Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives

Jonathan M Lehman; Pierre P aMassion

doi:10.18632/oncotarget.27107

Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives

Oncotarget. 2019 Jul 30;10(46):4727-4730. doi: 10.18632/oncotarget.27107.

Authors

Jonathan M Lehman^{1

2

3}, Pierre P aMassion^{1

2

3}

Affiliations

¹ Division of Medical Oncology, Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
² Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
³ Veterans Affairs, Tennessee Valley Healthcare System, Nashville Campus, Nashville, TN, USA.

Abstract

Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current clinical trial space, and describe promising new research and clinical directions for Somatostatin Receptor 2 targeting in SCLC.

Keywords: antibody-drug conjugate; peptide drug conjugate; perspectives; small cell lung cancer; somatostatin receptor 2.